Lilian Chow joins Cerecin as Vice President of Clinical Operations and Regulatory Affairs
SINGAPORE, 7 October 2019 – Cerecin, a global healthcare company focused on developing brain health solutions and therapeutics for patients around the world, today announced the appointment of Lilian Chow as Vice President, Clinical Operations and Regulatory Affairs with immediate effect.
Based in Singapore, Lilian will lead all clinical and regulatory operations for Cerecin, including the upcoming Phase 3 study of its lead drug formulation, tricaprilin, for use in Alzheimer’s disease. As Cerecin accelerates clinical development in Asia and globally, Lilian’s work will ensure executional excellence and efficiency. Lilian will also be an integral part of Cerecin’s business growth as it looks to develop unique therapeutics for the treatment of other neurodegenerative diseases.
Lilian brings more than 16 years of experience in clinical research, drug development and regulatory affairs, including clinical operations expertise in more than 20 countries across the US, Europe and Asia Pacific for Alzheimer’s disease and other CNS indications.
Lilian joins Cerecin from ASLAN Pharmaceuticals as Vice President, Clinical Operations, Research & Development, where she was responsible for leading the advancement of several investigational compounds in various stages of development for different oncological indications. Prior to ASLAN, she spent 8 years in various project management and operations roles with Lundbeck, a CNS therapeutics leader, including a role as Clinical Operations Manager reporting to the Copenhagen headquarters.
Commenting on the appointment, Judy Walker, Chief Medical Officer of Cerecin, said, “We are pleased to welcome Lilian to Cerecin as we prepare to bring our lead drug candidate into Phase 3 of clinical development. Lilian’s rich clinical operations experience and knowledge in CNS, and broad expertise across the drug development process will provide great support for Cerecin to continue to develop innovative treatments for sufferers of devastating neurological conditions, such as Alzheimer’s disease and ensure that these products find their way to the patients that need them most.”
Lilian Chow added: “Alzheimer’s is one of the most devastating diseases with no cure and only a handful of treatments. Being the largest unmet clinical need, it causes tremendous burden on patients, caregivers, and the healthcare systems across the globe. I am excited to join a team of experienced researchers and scientists to answer this challenge with Cerecin’s unique metabolic approach, which may ultimately provide better treatment options for patients globally”.
Lilian obtained a Bachelor of Science (Pharmacy) degree with Honors from National University of Singapore, and graduated from Queensland University of Technology, Australia with a Master’s degree in Management in Research & Development (Distinction).